Abivax news

Abivax is a French biotechnology company that focuses on the development of innovative treatments for infectious diseases and cancer. Here are some recent news and updates about Abivax:

Recent News:

  1. Abivax announces positive results from Phase 2 clinical trial of ABX464 in patients with moderate to severe Crohn's disease: In February 2023, Abivax announced that its Phase 2 clinical trial of ABX464, an oral therapy for Crohn's disease, met its primary endpoint and showed significant improvements in clinical remission and endoscopic response.
  2. Abivax receives €10 million grant from the French government to support the development of ABX464: In January 2023, Abivax announced that it had received a €10 million grant from the French government to support the development of ABX464, a potential treatment for Crohn's disease and other inflammatory bowel diseases.
  3. Abivax presents data on ABX464 at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting: In November 2022, Abivax presented data on ABX464 at the AASLD Annual Meeting, highlighting its potential as a treatment for non-alcoholic steatohepatitis (NASH) and other liver diseases.
  4. Abivax appoints new Chief Medical Officer: In October 2022, Abivax announced the appointment of Dr. Jean-François Rossignol as its new Chief Medical Officer, bringing over 20 years of experience in the pharmaceutical industry to the company.

Pipeline Updates:

  1. ABX464: Abivax's lead candidate, ABX464, is an oral therapy being developed for the treatment of Crohn's disease, ulcerative colitis, and other inflammatory bowel diseases. The company is currently conducting Phase 2 clinical trials for ABX464 in these indications.
  2. ABX196: Abivax is also developing ABX196, an oral therapy for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases. The company is currently conducting Phase 1 clinical trials for ABX196.

Financial Updates:

  1. Abivax raises €20 million in Series C financing: In June 2022, Abivax announced that it had raised €20 million in Series C financing to support the development of its pipeline, including ABX464 and ABX196.
  2. Abivax reports €15.6 million in revenue for 2022: In February 2023, Abivax reported its financial results for 2022, which included €15.6 million in revenue and a net loss of €24.4 million.

I hope this information is helpful!